Interview: Erich Lehner – Head of Life Science Branch, EY Austria
Erich Lehner, head of the life science branch at EY Austria, a worldwide leading consultancy firm, provides an insight into the current mandate of EY Austria as well as the…
EY is a global consultancy company foc committed to building a better working world – with increased trust and confidence in business, sustainable growth, development of talent in all its forms, and greater collaboration.EY is a global consultancy company foc committed to building a better working world – with increased trust and confidence in business, sustainable growth, development of talent in all its forms, and greater collaboration.
EY Life Sciences Network provides a global team of professionals to help companies make the most of their potential and lead their businesses into a successful future. EY Life Sciences Austria works in three key sectors: biotechnology, medical and pharmaceutical industry.
Contact
Wagramer Str. 19, 1220 Vienna, Austria
Tel +43 (1) 211 70-0
Website http://www.ey.com/at/de/home
Email ey@at.ey.com
Erich Lehner, head of the life science branch at EY Austria, a worldwide leading consultancy firm, provides an insight into the current mandate of EY Austria as well as the…
Some of the top recent stories from pharma and healthcare in the Middle East and Africa, including Saudi Arabia’s pharma pitch to US investors, a new fund to bring forward…
Manufacturing – long sidelined as a relatively prosaic element of the global pharma supply chain – is back in the news. Investment in manufacturing facilities is skyrocketing as sponsors rush…
When it comes to Denmark’s flourishing local biotech scene, the country is again clearly punching far above its weight. The EU member state has already managed to muster world-class expertise…
As kidney disease places mounting pressure on global healthcare systems, innovation in dialysis becomes all the more critical, especially for patients receiving therapy at home. Enter Vivatum: a Swiss-Swedish medtech…
Urs Indermühle sees 2025 shaped by three big shifts and two urgent risks: R&D is now mostly sourced externally (just 35 percent developed in‑house), forcing pharma to master licensing and…
With nearly half of Chinese adults now suffering from myopia and age-related eye conditions on the rise, China is on the brink of an ophthalmology boom — a market set…
Santen is on a mission to reshape the future of eye health. With three major product launches ahead, bold biotech deals, and a revamped global strategy, the Japanese pharma is…
A roundup of the biggest stories from Brazil’s pharma industry, including Teuto’s cannabis manufacturing deal with MediPharm; Eurofarma’s AI-based epilepsy joint venture with SK Biopharmaceuticals; EMS’s increased stake in Hypera…
Marianthi Psaha, President, Head of EMEA for Santen, discusses the company’s journey towards becoming a specialized leader in ophthalmology—highlighting how digital transformation, innovation in myopia treatment, and strategic partnerships are…
A roundup of the biggest pharma and healthcare stories from Turkey including the investigation of 19 pharma companies by the country’s competition watchdog; Gen Pharma Caucasus Manufacturing’s new plant in…
Pierre Fabre has been present in the Moroccan market for nearly 40 years. Pierre Behnam, the company’s director for Africa, Middle-East and Türkiye discusses its strategy for bringing innovation and…
First set up in 2014, the Guangdong Medical Valley is an investment incubation platform in southern China focusing on the biomedical and medical device industries. CEO Xia Jiasheng explains how…
See our Cookie Privacy Policy Here
